EP 80317, a ligand of the CD36 scavenger receptor, protects apolipoprotein E‐deficient mice from developing atherosclerotic lesions
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
CD36, a type B scavenger receptor expressed on macrophages, appears to play a major role in fatty streak formation through scavenging oxidatively modified lipoproteins in the arterial wall. We tested the hypothesis that EP 80317, a novel CD36 ligand derived from the growth hormone (GH)‐releasing peptide family but devoided of any GH releasing activity, exerts anti‐atherosclerotic effects in apolipoprotein E‐deficient (apoE −/− ) mice fed an atherogenic diet from 6 wk of age. Daily subcutaneous injections of EP 80317 (300 µg/kg) or vehicle were initiated at 6, 10, 12, or 14 wk until death at 18 wk. En face analyses of the entire aortic tree revealed a striking reduction (up to 51%) of lesion areas in EP 80317‐treated apoE −/− mice compared with controls. Chronic treatment with EP 80317 (12 wk) is also associated with a 30% decrease in total plasma cholesterol, suggesting potential effects of this drug on cholesterol metabolism at the intestine/hepatic levels. EP 80317 exerts both preventive and curative effects on atherosclerotic lesion progression that were shown to be reversible after cessation of treatment. At the macrophage level, EP 80317 reduced oxidized low density lipoproteins internalization and up‐regulated genes involved in cholesterol efflux, including peroxisome proliferator‐activated receptor γ (PPARγ), liver x receptor α (LXRα), and the ATP binding cassette (ABC) transporters ABCA1 and ABCG1, supporting a role in regulating peripheral cholesterol trafficking. Importantly, the effects of EP 80317 were shown to be CD36 dependent, inasmuch as no anti‐atherosclerotic or hypocholesterolemic effects were observed in apoE/CD36 double‐deficient mice. In addition, long‐term treatment of apoE/CD36 double‐deficient mice with EP 80317 did not modulate the expression of genes of the PPARγ‐LXRα‐ABC transporters pathway. Our results suggest that EP 80317, as a CD36 ligand, might be a prototype for a novel class of anti‐atherosclerotic agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree.
Nakashima, Y., Plump, A. S., Raines, E. W., Breslow, J. L., & Ross, R. (1994) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.14.1.133 · Cited by 1,693
A PPARγ-LXR-ABCA1 Pathway in Macrophages Is Involved in Cholesterol Efflux and Atherogenesis
Chawla, A., Boisvert, W. A., Lee, C.-H., Laffitte, B. A., Barak, Y., Joseph, S. B., Liao, D., Nagy, L., Edwards, P. A., Curtiss, L. K., et al. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00164-2 · Cited by 1,347
Chinetti, G., Lestavel, S., Bocher, V., Remaley, A. T., Neve, B., Torra, I. P., Teissier, E., Minnich, A., Jaye, M., Duverger, N., et al. (2001) · Nature Medicine · doi:10.1038/83348 · Cited by 1,170
A Null Mutation in Murine CD36 Reveals an Important Role in Fatty Acid and Lipoprotein Metabolism
Febbraio, M., Abumrad, N. A., Hajjar, D. P., Sharma, K., Cheng, W., Pearce, S. F. A., & Silverstein, R. L. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.27.19055 · Cited by 769
Self-citationThe macrophage foam cell as a target for therapeutic intervention
Li, A. C., & Glass, C. K. (2002) · Nature Medicine · doi:10.1038/nm1102-1235 · Cited by 700
Cited by
Hepatic Fatty Acid Transporter Cd36 Is a Common Target of LXR, PXR, and PPARγ in Promoting Steatosis
Zhou, J., Febbraio, M., Wada, T., Zhai, Y., Kuruba, R., He, J., Lee, J. H., Khadem, S., Ren, S., Li, S., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2007.11.037 · Cited by 605
Self-citationScavenger Receptors in Atherosclerosis: Beyond Lipid Uptake
Moore, K. J., & Freeman, M. W. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000229218.97976.43 · Cited by 562
CD36, a scavenger receptor implicated in atherosclerosis
Park, Y. M. (2014) · Experimental & Molecular Medicine · doi:10.1038/emm.2014.38 · Cited by 517
Park, Y. M., Febbraio, M., & Silverstein, R. L. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35535 · Cited by 406
Self-citationCD36 and macrophages in atherosclerosis
COLLOTTEIXEIRA, S., MARTIN, J., MCDERMOTTROE, C., POSTON, R., & MCGREGOR, J. (2007) · Cardiovascular Research · doi:10.1016/j.cardiores.2007.03.010 · Cited by 389
Metadata
- Authors
- Marleau, S., Harb, D., Bujold, K., Avallone, R., Iken, K., Wang, Y., Demers, A., Sirois, M. G., Febbraio, M., Silverstein, R. L., Tremblay, A., & Ong, H.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2005-08-25
- Volume
- 19
- Issue
- 13
- Pages
- 1869-1871
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W2154013127
- Cited by
- 115
- References
- 5
- FWCI
- 6.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: EP 80317, a ligand of the CD36 scavenger receptor, protects apolipoprotein E‐deficient mice from developing atherosclerotic lesions. https://app.cochat.ai/papers/10.1096/fj.04-3253fje
- The paper
- Marleau, S., Harb, D., Bujold, K., Avallone, R., Iken, K., Wang, Y., Demers, A., Sirois, M. G., Febbraio, M., Silverstein, R. L., Tremblay, A., & Ong, H. (2005). EP 80317, a ligand of the CD36 scavenger receptor, protects apolipoprotein E‐deficient mice from developing atherosclerotic lesions. The FASEB Journal. https://doi.org/10.1096/fj.04-3253fje
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.